CytoSorbents Corp. (NASDAQ: CTSO) Starts Presentation at 2017 Disruptive Growth & Healthcare Conference
CytoSorbents (NASDAQ: CTSO) is a critical care focused immunotherapy company engaged in the research, development and commercialization of medical devices with its platform blood purification technology that incorporates a proprietary adsorbent polymer technology. Its principal product is the CytoSorb device, an extracorporeal cytokine filter designed for the adjunctive therapy in the treatment of sepsis. CytoSorbent is also developing the HemoDefend blood purification technology platform to reduce contaminants in the blood supply that can cause transfusion reactions or disease when administering blood and blood products to patients. For more information, visit the company’s website at www.cytosorbents.com. About NetworkNewsWire NetworkNewsWire (NNW) provides…